Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multicenter, Randomized, Double-Blind, Phase 3 Study to Evaluate the Safety and Efficacy of a Gel Formulation of Esmolol Hydrochloride (Galnobax®) in Treating Diabetic Foot Ulcers

NCT03998436 is registered in ClinicalTrials.gov with Novalead Pharma Private Limited as lead sponsor.

NCT NCT03998436
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03998436 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multicenter, Randomized, Double-Blind, Phase 3 Study to Evaluate the Safety and Efficacy of a Gel Formulation of Esmolol Hydrochloride (Galnobax®) in Treating Diabetic Foot Ulcers
Lead sponsor
Novalead Pharma Private Limited
Phase
Phase 3
Overall status
Completed
Start date
December 26, 2018
Completion date
December 6, 2021
Enrollment
176 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic foot ulcer